Business mix
- Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
- The company was incorporated in 2013 and is headquartered in Paris, France.
Current key questions
- Can the company's products, services, or pipeline expand adoption within biotechnology?
- How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
- Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?